Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Entities / Myotonic dystrophy type 1
Other

Myotonic dystrophy type 1

Tracked across 1 events · 6 articles · First seen Jun 03, 2026 · Last active Jun 03, 2026

Sentiment
0
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 0
Business
Dyne Therapeutics Completes ACHIEVE Trial Enrollment
Dyne Therapeutics announced the completion of enrollment in the registrational expansion cohort of its Phase 1/2 ACHIEVE trial for zeleciment basivarsen (DYNE-101), an investigational therapeutic for Myotonic dystrophy type 1 (DM1). The cohort enrolled 71…
Impact: Myotonic dystrophy type 1 (DM1) is the genetic neuromuscular disease that zeleciment basivarsen aims to treat. The successful progression of the ACHIEVE trial offers hope for patients suffering from this rare and severe condition.
Jun 03, 2026 · 6 articles
NEWSDESK
Track Myotonic dystrophy type 1 live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.